HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G.
Pollara J, et al. Among authors: michael nl.
J Virol. 2014 Jul;88(14):7715-26. doi: 10.1128/JVI.00156-14. Epub 2014 May 7.
J Virol. 2014.
PMID: 24807721
Free PMC article.
Clinical Trial.